NEW YORK (GenomeWeb News) – Compugen will collaborate with Merck to develop a peptide that, based on recent in vitro and in vivo studies, potentially could be used in the treatment of inflammatory diseases and other indications.
The agreement covers additional research that Compugen will conduct on the CGEN-855 peptide, and gives Merck Serono an option to license it exclusively for worldwide development and commercialization.
Compugen said it discovered the peptide using its GPCR Peptide Ligands Discovery Platform. The Tel Aviv, Israel-based company also said that it currently has other peptide candidates “moving forward” in collaborations with Merck Serono, including ones that may be relevant to cancer, inflammation, metabolism, and cardiovascular disease.
Financial terms of the agreement were not released.